Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 75

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 75
---
 Agreement, as amended to date, and the transactions contemplated thereby (including the Business Combination) and (iii) recommended that Iris’s stockholders approve the Business Combination Agreement, as amended to date, and the transactions contemplated thereby. In reaching its decision with respect to the Business Combination, the Iris Board reviewed and considered a wide variety of factors, including various industry and financial data and certain due diligence and evaluation materials provided by legal counsel and independent advisors. In light of the complexity of those factors, the Iris Board, as a whole, did not consider it practicable to, nor did it attempt to, quantify or otherwise assign relative weights to the specific factors it took into account in reaching its decision. Individual members of the Iris Board may have given different weight to different factors. This explanation of the reasons for the Iris Board’s approval of the Business Combination, and all other information presented in this section, is forward-looking in nature and, therefore, should be read in light of the factors discussed under “ Forward-Looking Statements .” Before reaching its decision, the Iris Board reviewed the results of the due diligence conducted by Iris management, legal counsel, and independent advisors, which included: • Iris’s management had numerous meetings with Liminatus regarding, among other customary due diligence matters, Liminatus’s brand, products, clinical trials and results, intellectual property, public company preparedness, operations, market access and distribution, financials and use of proceeds, competitors, plans, and forecasts. • A review of Liminatus’s material contracts and other documentation, including but not limited to those relating to intellectual property, regulatory compliance, and other legal matters. • A review of safety data, preclinical trial data, clinical trial data, and study reports. • A review of Liminatus’s intellectual property rights, including but not limited to license agreements, patent portfolio status, and patent strategy. • A review of Liminatus’s upcoming products, expedited pathways available to Liminatus, and consideration of the likelihood of success given Liminatus’s clinical trial data and alternatives in the market, among other considerations. • A review of Liminatus’s financial statements and internal reports.

11

TABLE OF CONTENTS

•

A review of other biotech companies operating in the same or similar market as Liminatus.

•

A review of industry trends in the biopharmaceutical market and a historical comparison of similar business combinations.

The factors considered by the Iris Board included, but were not limited to, the following:

Potential to Grow Globally

We